This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paggi, M. G. Articles by Felsani, A. Search for Related Content PubMed PubMed Citation Articles by Paggi, M. G. Articles by Felsani, A.

The Retinoblastoma Gene Product in Acute Myeloid Leukemia: A Possible Involvement in Promyelocytic Leukemia¹

Laboratories of Cellular Metabolism and Pharmacokinetics [M. G. P., F. B., L. A., A. Fl.], Molecular Biology [A. Fe.], and Medical Physics [F. P. G.], Experimental Research Center, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Via delle Messi d'Oro, 156, 00158 Rome; Biomedical Technology Institute, Consiglio Nazionale delle Ricerche, Via Morgagni 30/E, 00161 Rome [A. Fe., G. S.]; Cattedra di Ematologia, Università degli Studi "La Sapienza," 00161 Rome [P. d. F., A. S.]; and Department of Experimental Medicine, Coppito 2, Università de L'Aquila, 67100 L'Aquila [A. Fl.], Italy

The retinoblastoma susceptibility gene in leukemia and lymphoma has been investigated using different approaches involving either gene or protein analysis. In this study, a novel method, which evaluates the functional status of the retinoblastoma gene product by a binding assay to an in vitro-translated viral oncoprotein, has been applied to leukemic cells from acute myeloid leukemia patients. One hundred twenty-two cases were considered, and 42 of them were also analyzed by Western blot. Results obtained with the two methods were comparable, with the exception of few cases, where the retinoblastoma protein appeared detectable but unable to bind to the viral oncoprotein. The retinoblastoma protein has been found defective mostly in the M3 promyelocytic subtype.

¹ This work was supported by the Progetto Finalizzato Applicazioni Cliniche della Ricerca Oncologica and Ingegneria Genetica, Consiglio Nazionale delle Ricerche, Rome, Italy, and by the Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy. F. B. is an AIRC postdoctoral fellow.

² To whom requests for reprints should be addressed, at Laboratory of Cellular Metabolism and Pharmacokinetics, Experimental Research Center, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Via delle Messi d'Oro, 156, 0158 Rome, Italy. Phone: (+39-6) 4985.2550; Fax: (+39-6) 418.0473; E-mail: paggi@dotto.ifo.it.

Received 7/ 7/95. Accepted 8/30/95.

This article has been cited by other articles:

				M. M. Khan, T. Nomura, H. Kim, S. C. Kaul, R. Wadhwa, S. Zhong, P. Paolo Pandolfi, and S. Ishii PML-RARalpha Alleviates the Transcriptional Repression Mediated by Tumor Suppressor Rb J. Biol. Chem., November 16, 2001; 276(47): 43491 - 43494. [Abstract] [Full Text] [PDF]

				J. L. Grisolano, R. L. Wesselschmidt, P. G. Pelicci, and T. J. Ley Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RARalpha Under Control of Cathepsin G Regulatory Sequences Blood, January 15, 1997; 89(2): 376 - 387. [Abstract] [Full Text] [PDF]